Skip to main content
SpringerLink
Log in

Diclofenac/Misoprostol

Pharmacoeconomic Implications of Therapy

  • Adis Formulary Perspective
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The combined formulation of diclofenac/misoprostol provides effective relief of pain and inflammation, with a 2- to 3-fold lower incidence of NSAID-associated gastroduodenal ulcers than diclofenac monotherapy.

Both components of the combined formulation have been widely used and have well documented efficacy and tolerability profiles. Compared with other agents used as prophylaxis for NSAID-induced gastropathies,misoprostol is generally considered to have the most extensive outcomes data establishing its efficacy in preventing both gastric and duodenal ulcers associated with long term NSAID use.

Economic analyses conducted to date have shown that diclofenac/misoprostol is associated with similar or lower total directmedical treatment costs compared with other NSAIDs (with or without coprescribed misoprostol or an alternate prophylactic agent). As with pharmacoeconomic studies of coprescribed misoprostol with NSAIDs, the most favourable results with the combined formulation of diclofenac/misoprostol appear to be in patients at high risk of developing NSAID-associated gastroduodenal ulcers (e.g. the elderly).

Although economic analyses with diclofenac/misoprostol were conducted in several different countries using a variety of methodologies and employing a wide range of clinical and economic assumptions, results have been generally favourable for the combined formulation. However, as is the case with pharmacoeconomic analyses in general, results of individual studies with diclofenac/misoprostol may not be generalisable between countries and are subject to change over time.

Overall, clinical and economic data suggest that the optimal and most costeffective use of the combined formulation of diclofenac/misoprostol is in patients requiring long term NSAID therapy who are at increased risk of developing NSAID-induced gastropathy, such as elderly patients with rheumatoid arthritis or osteoarthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995 Nov; 7: 372–93

    Article  PubMed  CAS  Google Scholar 

  2. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum 1995 Jan; 38: 5–18

    Article  PubMed  CAS  Google Scholar 

  3. Zeidler H. Epidemiology of NSAID-induced gastropathy. Clin Rheumatol 1991 Dec; 10: 369–73

    Article  PubMed  CAS  Google Scholar 

  4. Goldstein JL, Larson LR, Yamashita BD. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol. Am J Managed Care 1998; 4: 687–97

    CAS  Google Scholar 

  5. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 1019–22

    Article  PubMed  CAS  Google Scholar 

  6. Agrawal NM. Anti-inflammatories and gastroduodenal damage: therapeutic options. Eur J Rheumatol Inflamm 1993; 13 (1): 17–24

    PubMed  CAS  Google Scholar 

  7. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647–55

    PubMed  CAS  Google Scholar 

  8. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991 Sep; 91: 213–22

    Article  PubMed  CAS  Google Scholar 

  9. Committee on Safety of Medicines. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions: 2. BMJ 1986; 292: 1190–1

    Article  Google Scholar 

  10. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal Anti-inflammatory drugs. Arthritis Rheum 1991; 34 (11): 1353–60

    Article  PubMed  CAS  Google Scholar 

  11. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8

    Article  PubMed  CAS  Google Scholar 

  12. García Rodríguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998 Mar 30; 104 (3A): 30S-4S

    Article  Google Scholar 

  13. Willett LR, Carson JL, Strom BL. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Saf 1994 Feb; 10: 170–81

    Article  PubMed  CAS  Google Scholar 

  14. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359–63

    PubMed  CAS  Google Scholar 

  15. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann InternMed 1991; 114: 257–63

    CAS  Google Scholar 

  16. Walt R, Katschinski B, Logan R, et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986; I: 489–92

    Article  Google Scholar 

  17. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713–22

    Article  Google Scholar 

  18. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for The medical management of osteoarthritis. Part 1.Osteoarthritis of the hip. Arthritis Rheum 1995; 38: 1535–40

    Article  PubMed  CAS  Google Scholar 

  19. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1541–6

    Article  PubMed  CAS  Google Scholar 

  20. Tannenbaum H, Davis P, Russell AS, et al. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Can Med Assoc J 1996; 155 (1): 77–88

    CAS  Google Scholar 

  21. Lanza FL. Prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions: a commentary on the new data. Am J Med 1998; 104 (3A): 75S-8S

    Article  Google Scholar 

  22. Scheiman J, Isenberg J. Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers. Am J Med 1998; 105 (5A): 32S-8S

    Article  Google Scholar 

  23. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: mulitcentre, double-blind, placebo-controlled trial. Lancet 1988 Dec 3; II: 1277–80

    Article  Google Scholar 

  24. Elliott SL, Yeomans ND, Buchanan RRC, et al. Efficacy of 12 months’ misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol 1994; 23: 171–6

    Article  PubMed  CAS  Google Scholar 

  25. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257–62

    PubMed  CAS  Google Scholar 

  26. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug 15; 123: 214–49

    Google Scholar 

  27. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344–50

    PubMed  CAS  Google Scholar 

  28. Geis GS, Stead H, Wallemark CB, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol 1991; 28 Suppl.: 11–4

    CAS  Google Scholar 

  29. de Pouvourville G. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy. Br J Rheumatol 1995; 34 Suppl. 1: 19–24

    PubMed  Google Scholar 

  30. Maetzel A, Bosi Ferraz M, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1998; 41 (1): 16–25

    Article  PubMed  CAS  Google Scholar 

  31. Barradell LB, Whittington R, Benfield P. Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. Pharmacoeconomics 1993 Feb; 3: 140–71

    Article  PubMed  CAS  Google Scholar 

  32. McKenna F. Efficacy and gastroduodenal safety of a fixed combination of diclofenac and misoprostol in the treatment of arthritis. Br J Rheumatol 1995 Apr; 34 Suppl. 1: 11–8

    PubMed  Google Scholar 

  33. McKenna F. Diclofenac/misoprostol: the European clinical experience. J Rheumatol 1998; 25 Suppl. 51: 21–30

    Google Scholar 

  34. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998; 25: 1602–11

    PubMed  CAS  Google Scholar 

  35. Bolten W, Melo Gomes JA, Stead H, et al. The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. Br J Rheumatol 1992; 31: 753–8

    Article  PubMed  CAS  Google Scholar 

  36. Stead H, Morant SV, Shield MJ. The combination drug diclofenac 75mg/misoprostol 200 g provides equivalent antiarthritic efficacy to diclofenac 75mg SR in RA and OA but with an improved safety profile [abstract]. Rheumatol Eur 1996; 24 Suppl. 3: 220

    Google Scholar 

  37. Verdickt W, Moran C, Hantzchel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 21: 85–91

    Article  PubMed  CAS  Google Scholar 

  38. Bocanegra TS, Kivitz A, Hurley SM, et al. Treatment of osteoarthritis (OA with diclofenac/misoprostol is associated with a lower incidence of gastroduodenal ulcers (GDU) compared to nabumetone and naproxen [abstract no. 985]. Arthritis Rheum 1998; 41 Suppl.: S197

    Google Scholar 

  39. Kiff PS, Stead H, Morant V, et al. Arthrotec, diclofenac, and ibuprofen in general practice. Eur J Rheumatol Inflamm 1994; 14 Suppl.: 31–8

    PubMed  CAS  Google Scholar 

  40. McKenna F, Allan L, Kiff PS. Diclofenac/misoprostol and indomethacin - efficacy and GI damage in rheumatoid arthritis and ankylosing spondylitis [abstract]. Rheumatol Eur 1995; 24 Suppl. 3: 220

    Google Scholar 

  41. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993 Dec; 52: 881–5

    Article  PubMed  CAS  Google Scholar 

  42. Gabriel SE, Matteson EL. Economic and quality-of-life impact of NSAIDs in rheumatoid arthritis: a conceptual framework and selected literature review. Pharmacoeconomics 1995 Dec; 8: 479–90

    Article  PubMed  CAS  Google Scholar 

  43. Gabriel SE, Wagner JL. Costs and effectiveness of nonsteroidal anti-inflammatory drugs: the importance of reducing side effects. Arthritis Care Res 1997 Feb; 10: 56–63

    Article  PubMed  CAS  Google Scholar 

  44. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988 Feb 22; 84: 20–4

    Article  Google Scholar 

  45. Kendall BJ, Peura DA. NSAID-associated gastrointestinal damage and the elderly. Article five in the series. Pract Gastroenterol 1993; 17: 13–29

    Google Scholar 

  46. Gabriel SE, Campion ME, O’Fallon WM, et al. The health care costs of nonsteroidal anti-inflammatory drug-related gastric ulcer in Olmsted County, MN, 1987–1990. Post Market Surveill 1992 Nov; 6: 135–46

    Google Scholar 

  47. Johnson RE, Hornbrook MC, Hooker RS, et al. Analysis of the costs of NSAID-associated gastropathy: experience in a US health maintenance organisation. Pharmacoeconomics 1997; 12 (1): 76–88

    Article  PubMed  CAS  Google Scholar 

  48. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997 Aug; 40: 1475–81

    Article  PubMed  CAS  Google Scholar 

  49. McCabe CJ, Akehurst RL, Kirsch J, et al. Choice of NSAID and anagement strategy in rheumatoid arthritis and osteoarthritis: the impact on costs and outcomes in the UK. Pharmacoeconomics 1998; 14 (2): 191–9

    Article  PubMed  CAS  Google Scholar 

  50. de Pouvourville G. The economic consequences of NSAID induced gastrointestinal damage. Br J Med Econ 1992; 2: 93–102

    Google Scholar 

  51. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061–5

    Article  PubMed  CAS  Google Scholar 

  52. Jönsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992; 8: 234–44

    Article  PubMed  Google Scholar 

  53. De Pouvourville G. Preventing NSAID-induced gastrointestinal toxicity: economic considerations, methodological problems and results. Pharmacoeconomics 1995 Feb; 7: 99–110

    Article  PubMed  CAS  Google Scholar 

  54. Stucki G, Johannesson M, Liang MH. Use of misoprostol in the elderly: is the expense justified? Drugs Aging 1996; 8 (2): 84–8

    Article  PubMed  CAS  Google Scholar 

  55. Al MJ, Michel BC, Rutten FFH. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. Pharmacoeconomics 1996 Aug; 10: 141–51

    CAS  Google Scholar 

  56. Goldstein JL, Larson LR, Yamashita BD, et al. Management of NSAID-induced gastropathy: an economic decision analysis. Clin Ther 1997 Nov-Dec; 19: 1496–509

    Article  PubMed  CAS  Google Scholar 

  57. Goldstein JL, Yamashita BD, Larson LR. Diclofenac/misoprostol vs. PPI prophylaxis in the prevention of NSAID-induced complications: a cost model comparison [abstract]. Gastroenterology 1998; 114: A136

    Google Scholar 

  58. Goldstein JL, Stewart D, Zabinski RA, et al. The economic implications of decreased patient adherence to co-prescribed diclofenac andmisoprostol (CoRx-D&M) relative to a single-tablet formulation of diclofenac/misoprostol (STF-D/M) [abstract]. Value in Health 1998; 1 (1): 57

    Article  Google Scholar 

  59. Annemans L, Vanoverbeke N, Van Rompay W. Cost-effectiveness analysis of a fixed combination (diclofenac + misoprostol) in the prevention of gastropathy in arthritis patients in Belgium [abstract]. Value in Health 1999; 2 (1): 38

    Article  Google Scholar 

  60. Sclar DA, Robison LM, Maheu A, et al. Prescribing rationale and budgetary outcomes associated with the introduction of a combined formulation of diclofenac sodium and misoprostol in Canada. J Int Med Res 1995 Nov-Dec; 23: 439–48

    PubMed  CAS  Google Scholar 

  61. Knill-Jones R. An economic evaluation of Arthrotec in the treatment of arthritis. Br J Med Econ 1992; 5: 51–8

    Google Scholar 

  62. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307–14

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Greg L. Plosker & Harriet M. Lamb

Authors
  1. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harriet M. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Greg L. Plosker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plosker, G.L., Lamb, H.M. Diclofenac/Misoprostol. Pharmacoeconomics 16, 85–98 (1999). https://doi.org/10.2165/00019053-199916010-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199916010-00008

Search

Navigation